Manage Account - ModernMedicine

Medicare not likely to cover bevacizumab treatment
Publish date: February 15, 2006
By: Jennifer A. Webb
Source:

New York—Ophthalmologists who choose to use bevacizumab (Avastin, Genentech) for off-label treatment of wet age-related macular degeneration (AMD) should not expect Medicare to reimburse those expenses, according to George A. Williams, MD.

The journal page you requested is now available only to registered Modern Medicine members.

Register Here

Registration is Free!
(and Takes Less than a Minute)

RegisterUS Physicians, click here
for express registration.

RegisterHealthcare Professionals,
click here

Modern Medicine Offers:
» Practice Management Advice
» CME / ICD-9 Coding / Formulary
» Patient Education Handouts
» Peer-reviewed Articles
» Conference Coverage, Email Alerts & More

Click Here to Watch the Tour

Already Registered?

Login Now

Login Email:Password:
Forgot Your Password?Remember me.
Source: Ophthalmology Times, 2/15/2006
Click here